Nanox — Trading Ideas on TradingView

All Red - $NNOX Long - But Nanox's Biggest Issue Right Now The problem with Nanox, which is also likely why they recently had a stock sale, is likely the need of cash for further distribution. They are in the red and still have long ways to go. That said, when the market dips, Nanox seriously dips. Beyond just the recent France deal, a catalyst is needed to further push Nanox further. That said, I believe we could be long overdue for a bull run. As always, none of this is investment or financial advice. Please do your own due diligence and research.

My Sentiment for $NNOX is Still Long Nanox Imaging is one of those stocks I lost long term in, and kind of got attached to. However, my sentiment based on their tech and acquisitions is still long. The biggest issue is short sale volume, the need for better PR and faster project updates, the loss of their founder, and uncertainty of the future of Nanox Imaging along with the high risk in biotech. $18.41 as a target by 2027 is still feasible, however, NASDAQ:NNOX has to deliver. They have long ways to go to revamp their brand image after what happened with short sellers. As always, none of this is investment or financial advice. Please do your own due diligence and research.

Can X-Ray Technology Really Disrupt a 125-Year-Old Industry?Nano-X Imaging is attempting to fundamentally restructure the medical imaging industry through a convergence of semiconductor innovation and business model disruption. The company has commercialized a cold cathode X-ray source that replaces the century-old thermionic emission technology, which wastes 99% of energy as heat, with field emission from millions of molybdenum nano-cones operating at room temperature. This breakthrough, manufactured in their South Korean semiconductor fabrication facility near the SK Hynix cluster, enables the Nanox.ARC system: a compact, digitally-agile tomosynthesis device that eliminates the need for massive cooling systems and rotating gantries that have defined traditional CT scanners. The commercial strategy centers on "Medical Screening as a Service" (MSaaS), converting imaging from a capital expenditure to an operational expense, which is particularly advantageous in the current high-interest-rate environment, where hospitals face capital budget constraints. Strategic partnerships provide immediate market access: the 3DR Labs agreement connects Nanox to over 1,800 US hospitals, integrating FDA-cleared AI algorithms (HealthCCSng, HealthOST, HealthFLD) directly into existing radiology workflows, while international deployments span Mexico (630 units with SPI Medical), South Korea and Vietnam (2,500 systems supported by SK Telecom), and European reference sites in France. Management has issued ambitious guidance of $35 million in revenue for 2026, representing approximately 900% growth from 2025 levels, progressing toward a projected $72.6 million by 2028. The investment thesis rests on technological validation (FDA 510(k) clearance, operational semiconductor fab), geopolitical resilience (supply chain decoupled from Middle East instability), and macroeconomic alignment (OpEx-based model favored during capital constraints). However, execution risks remain significant: the company maintains a substantial cash burn rate ($30.4 million in negative operating cash flow), requires continued capital raises (most recently, a $15 million offering), and faces adoption uncertainty as hospitals evaluate this novel service model. Analyst sentiment is bullish with price targets averaging $7.75 (120%+ upside), though more aggressive projections reach $23, contingent on the successful scaled deployment of the recurring revenue model that fundamentally challenges the traditional equipment sales paradigm of incumbent manufacturers like GE, Siemens, and Philips.

$NNOX Receives FDA 510K, Next Big Catalyst?The stock that I like so much finally received FDA 510K on the Nanox.ARC X-ray system. As much as it been short-selled into the ground, I am still heavily invested in it, and I think many of the catalyst in terms of early market and tech validation have already passed. It may not be smooth sailing, but I am still interested in Nanox for the long term, and am still here. That said, none of this is financial or investment advice. Information provided is "as-is". Do your own due-diligence.

This Could Be a Great Long Term Bet Nanox have been short-selled quite alot, and then you have this + the combination of hyperinflation and a recessive economy. However, Nanox is an Isreali company. The Nanox Korea building construction has been completed . While it may be a risky bet, now may be the time to get in. That said, please invest at your own risk. Do your own due diligence and everything said here is on an opinion-based basis.

$NNOX, Wait for the Catalyst + Short Squeeze (Low Volume)Nanox has been shortened alot, and now oversold on low volume. Looking at the RSI, it is quite low, and due for a breakout. Outside of this, I believe it has been announced that they have pre-orders for within the range of 15k machines. This accounts to what could be $1 billion in mostly revenue, if I understand currently from what has been said about the JP Morgan Virtual Conference. At the current market cap of $2.3B, this puts them likely under their fair overall enterprise value. Currently, FDA approval is a major catalyst that should be "soon" in regards to single source if everything goes well. Multi-source could be in the first half of 2021. It is currently a waiting game in regards to catalyst. There are also other big catalyst such as a factory announcement that may happen soon. Regarding patterns, I think overall a bullish setup is there. Currently, I am long. That said, do your own due diligence and invest at your own risk.

The $115+ NNOX Target + Patterns $NNOX is one of those volatile stocks that took the world by storm. If you don't like volatility, it is likely best to stay away from biotech or healthcare. That said, there are alot of expected catalysts. $NNOX have been heavily shortened, and it is in the opinion of many that lots of market manipulation has been and is going on. The short interest is low and the borrow rate is high. Currently as I see it, the pattern is still incrementally upwards. Nanox has the catalyst of factory announcements, FDA approvals for both single and multisource, plus the commencement of "device leasing". Currently with 4 catalyst, three of them that are expected to be big, a target of $115 seems reasonable. Support levels should be picking up soon, and unless one wants to flip for few cents or dollars per share as profit, this currently seems much better suited for a long term position. That said, I am long. Everything I say is on an opinion based basis. Please do your own due diligence and proceed with caution. Opinions mentioned here aren't meant to warrant solicited financial advice.

I Might Be Super Long for NNOX NNOX is one of those IPOs that were interesting me. I got in at $22.53 in one account, and averaging $24.49 in another. I exited out in one account at roughly $30.25 and the other at $29.50 near the peak. I did a rentry recently at $24.96, and was going to put a sale of $28.50 but decided to cancel that one and go in long. NNOX seems to be interesting to someone like me in terms of overall long term potential. I am doing research in similar markets so I know the sensors they want to provide are relatively basic compared to what is out there. The value proposition seems to be instead of using technology in the 80s and 90s to power medical imaging devices, use technology from the 2000s. They seem to be having a highly realistic value proposition from a technological standpoint. WalletInvestor recently came out with ludicrously large 1 year and 5 year targets for them, and the Montley Fool recently seemed to nickname them the "Tesla of Medical Imaging". Those are two popular resources seeming to add to people's bullishness. Given what has been said, I expect Nanox Imaging to garnish higher support levels. The sentiment seems positive as of now, and I don't expect major resistance patterns too soon. Also, I don't see reasons why the FDA might reject their device or the FCC might have a problem, given that more than likely this may emit less radiation than typical medical imaging machinery. That being said, everything I am saying is on an opinion based basis. Please do your own due diligence, invest at your own risk, and proceed with caution.